In Melbourne, Australia, the drug company Biota reported initial success with its new antiviral drug, Vapendavir.
Tested on 300 asthmatic patients infected with the cold-causing human rhinovirus, a clinical trial using Vapendavir showed that cold symptoms eased quickly and the time of the infection was shortened.
Dr. Robert Stirling, from Melbourne's Alfred Hospital, said: "If this reduces the intensity and duration of a respiratory cold, especially in asthmatics, it is an important finding."
"I think eventually we will be able to incorporate this treatment into our usual practice and we will find the economic benefits will outweigh health costs of treating infected patients."
Vapendavir still has to be tested in a larger group of patients, before it is available to the public.
Until this possible cure is approved, try checking out some home remedies atNaturalFamilyOnline.com.